News for Alpine Immune Sciences, Inc. (ALPN)

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% from its record high at the time of writing, Vertex shares have outperformed, up 20% year to date. Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales.

Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, biotech stocks can be highly volatile. Here's why I think Vertex Pharmaceuticals (NASDAQ: VRTX) is the ultimate biotech stock to buy with $500 right now.

These profitable companies are facing long-term growth runways.

Advancements and Projections in the Pharmaceutical Intermediates Market: Insights, Trends, Opportunities, and Recent Developments...

Travere's financial health is precarious, with significant losses and a potential need for additional funding, but a buyout could be a favorable outcome. Read more here.

The PGIM Jennison Health Sciences Fund advanced and outperformed the index during June. Read more here.

Enthusiasm about artificial intelligence helped drive collective gains in global equities during the second quarter of 2024. Click here to read the full fund letter.

Vertex Pharmaceuticals Inc (VRTX) faces a significant net loss due to substantial R&D investments.Despite a net loss, Vertex maintains a strong product revenue

Earnings call: Vertex Pharmaceuticals posts solid Q2 growth, updates pipeline

Vertex Reports Second Quarter 2024 Financial Results

Earnings call: Lazard announced a net revenue increase to $1.4 billion

PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial

Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

These healthcare stocks can provide enviable long-term portfolio growth.

NEW YORK, April 27, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and...

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...

Kuehn Law investigates INRD, AIRC, ELYM, ALPN mergers. Shareholders urged to contact for legal assistance....

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.